Dry eye disease is an ocular condition where the eyes do not produce enough tears or make the right type of tears or tear film. It is estimated that there are approximately 39 million dry eye disease patients in the United States.
The stock we are bringing to your attention today is that of Aldeyra Therapeutics Inc. (ALDX), which despite facing an initial setback in obtaining FDA approval for its investigational dry eye disease treatment last year, is set to make another attempt later this year.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com